Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB1 cannabinoid receptor

Molecular Pharmacology

Volumn 57, Issue 4, 2000, Pages 746-752

  Rhee, Man Hee ^a   Nevo, Igal ^a   Avidor Reiss, Tomer ^a   Levy, Rivka ^a   Vogel, Zvi ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR; CANNABINOID RECEPTOR; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOENZYME; PERTUSSIS TOXIN; PHOSPHOTRANSFERASE; RIMONABANT; THYROTROPIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

EID: 0034106410     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.57.4.746     Document Type: Article

References (45)

1. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 46:575-579.
2. Ammer H and Schulz R (1993) Alterations in the expression of G-proteins and regulation of adenylate cyclase in human neuroblastoma SH-SY5Y cells chronically exposed to low-efficacy μ-opioids. Biochem J 295:263-271.
3. Avidor-Reiss T, Bayewitch M, Levy R, Matus-Leibovitch N, Nevo I and Vogel Z (1995a) Adenylylcyclase supersensitization in μ-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem 270: 29732-29738.
4. Avidor-Reiss T, Nevo I, Levy R, Bayewitch ML and Vogel Z (1997) Opioid-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 272:5040-5047.
5. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T and Vogel Z (1996) Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gβγ. J Biol Chem 271:21309-21315.
6. Avidor-Reiss T, Zippel R, Levy R, Saya D, Ezra V, Barg J, Matus-Leibovitch N and Vogel Z (1995b) κ-Opioid receptor-transfected cell lines: Modulation of adenylyl cyclase activity following acute and chronic opioid treatments. FEBS Lett 361:70-74.
7. Bayewitch ML, Avidor-Reiss T, Levy R, Pfeuffer T, Nevo I, Simonds WF and Vogel Z (1998) Inhibition of adenylyl cyclase isoforms V and VI by various Gβγ subunits. FASEB J 12:1019-1025.
8. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G and Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for new model of receptor/ligand interaction. J Biol Chem 272:22330-22339.
9. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873.
10. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73:2447-2459.
11. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102:156-162.
12. Crespo P, Xu N, Simonds WF and Gutkind JS (1994) Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits. Nature (Lond) 369:418-420.
13. 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 47:33-40.
14. Diana M, Melis M, Muntoni A and Gessa G (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269-10273.
15. Dill JA and Howlett AC (1988) Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244:1157-1163.
16. Fan F, Tao Q, Abood M and Martin BR ( 1996) Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 706:13-20.
17. Gérard CM, Mollereau C, Vassart G and Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-134.
18. s linkage to the CB1 receptor. J Neurosci 17:5327-5333.
19. Glatt CE and Snyder SH (1993) Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature (Lond) 361:536-538.
20. 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J Pharmacol Exp Ther 252:1075-1082.
21. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634.
22. Koob GF, Sanna PP and Bloom FE (1998) Neuroscience of addiction. Neuron 21: 467-476.
23. Landsman RS, Burkey T, Consroe P and Yamamura HI (1997) SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334: R1-2.
24. Mackie K, Lai Y, Westenbroek R and Mitchell R (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561.
25. Maneuf YP and Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
26. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (Lond) 346:561-564.
27. Mons N and Cooper DMF (1995) Adenylate cyclases: Critical foci in neuronal signaling. Trends Neurosci 18:536-542.
28. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
29. Nestler EJ and Aghajanian GK ( 1997) Molecular and cellular basis of addiction. Science (Wash DC) 278:58-63.
30. Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Heldman E and Vogel Z (1998) Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors. Mol Pharmacol 64:419-426.
31. i-coupled receptors in vitro. J Biol Chem 271:33308-33316.
32. Oviedo A, Glowa J and Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Res 616:293-302.
33. Premont RT (1994) Identification of adenylyl cyclases by amplification using degenerate primers. Methods Enzymol 238:116-127.
34. Rhee M-H, Bayewitch ML, Avidor-Reiss T, Levy R and Vogel Z (1998) Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 71:1525-1534.
35. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
36. Sharma SK, Klee WA and Nirenberg M (1975) Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 72:3092-3096.
37. Simonds W (1999) G protein regulation of adenylate cyclase. Trends Pharmacol Sci 20:66-73.
38. Sunahara RK, Dessauer CW and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480.
39. Tanda G, Pontieri FE and Di Chiara G ( 1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science (Wash DC) 276:2048-2050.
40. Tang WJ and Gilman AG (1991) Type-specific regulation of adenylyl cyclase by G protein βγ subunits. Science (Wash DC) 254:1500-1503.
41. Thomas JM and Hoffman BB (1987) Adenylate cyclase supersensitivity: A general means of cellular adaptation to inhibitory agonists? Trends Pharmacol Sci 8:308-311.
42. Thomas JM and Hoffman BB (1996) Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: Role of βγ subunits in transducing enhanced activity of the type VI isoform. Mol Pharmacol 49:907-914.
43. Tsou K, Brown S, Sanudo-Pena MC and Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411.
44. Varga EV, Stropova D, Rubenzik M, Wang M, Landsman RS, Roeske WR and Yamamura HI (1998) Identification of adenylyl cyclase isoenzymes in CHO and B82 cells. Eur J Pharmacol 348:R1-R2.
45. Vogel Z, Barg J, Levy R, Saya D, Heldman E and Mechoulam R (1993) Anandamide, a brain endogenous compound, interacts specially with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61:352-355.